New York, May 16, 2026, 17:04 EDT
- Johnson & Johnson closed Friday down 1.77% at $226.71, but still gained about 2.4% for the week.
- The NYSE is shut for the weekend, with regular core trading set for 9:30 a.m. to 4:00 p.m. Eastern Time on exchange days.
- Investors head into next week watching fresh pipeline presentations and a medtech launch, not a new earnings print.
Johnson & Johnson shares enter the new week off Friday’s low but with a weekly gain intact, after the drug and medical-device maker fell 1.77% to $226.71 in a broad market selloff.
The move matters because J&J had climbed through most of the week, closing at $221.43 on Monday, $224.26 on Tuesday, $230.42 on Wednesday and $230.80 on Thursday before Friday’s drop, according to Investing.com historical data. The stock still finished about 2.4% above its May 8 close.
The pullback also came with the market closed for the weekend, leaving investors to weigh whether Friday was mainly index pressure or the start of a reset in healthcare. The S&P 500 fell 1.24% on Friday, while Johnson & Johnson peers Pfizer and Merck lost 1.63% and 1.79%, respectively, according to MarketWatch reports on Friday trading.
The week-ahead story is less about a single catalyst and more about whether J&J can keep investors focused on pipeline depth. The company said 18 neuropsychiatry abstracts would be presented at the American Psychiatric Association meeting from May 16-20 in San Francisco and the American Society of Clinical Psychopharmacology meeting from May 26-29 in Miami.
“At Johnson & Johnson, we are focused on addressing the residual symptoms that standard treatments often miss,” Jane Tiller, global head of development for neuroscience at J&J’s Innovative Medicine unit, said in the company’s May 11 announcement. The presentations include CAPLYTA data in schizophrenia and seltorexant analyses in major depressive disorder with insomnia symptoms. Johnson & Johnson Investor Relations
J&J’s medtech arm also has a fresh product story. The company said on May 12 it had launched its Shockwave C2 Aero Coronary IVL Catheter globally; IVL, or intravascular lithotripsy, uses acoustic pressure waves to crack hardened calcium in arteries so doctors can restore blood flow more easily.
“Shockwave C2 Aero makes it easier to navigate tortuous coronary anatomy,” said Margaret McEntegart, director of the Complex Percutaneous Coronary Intervention Program at Columbia University Medical Center/New York-Presbyterian Hospital. Isaac Zacharias, president of Shockwave Medical at J&J MedTech, said the company was “redefining standards for coronary IVL” as rivals prepare to enter the market. JNJ.com
The broader earnings backdrop remains supportive, though not fresh. J&J reported first-quarter sales of $24.1 billion in April, up nearly 10% from a year earlier, and raised its 2026 outlook to estimated reported sales of $100.8 billion and adjusted earnings per share of $11.55 at the midpoint. Chief Executive Joaquin Duato said the company had a “strong start to 2026.” Johnson & Johnson Investor Relations
But the downside case is not hard to find. Stelara, once a blockbuster autoimmune drug, is losing ground after patent protection ended; a biosimilar is a lower-cost near-copy of a complex biologic medicine. Reuters reported last month that Stelara sales fell about 60% to $656 million in the first quarter, even as Darzalex and Tremfya helped offset the decline.
Chief Financial Officer Joseph Wolk told Reuters many patients were choosing treatments such as Tremfya instead of switching to biosimilars, while Jennifer Taubert, J&J’s executive vice president, said the newly approved psoriasis drug Icotyde was off to “a very fast start” and had the potential to become one of the company’s biggest products. Reuters
That leaves the stock in a familiar place for a large healthcare name: protected by scale and dividends, but still exposed to product-cycle proof. J&J raised its quarterly dividend by 3.1% in April to $1.34 a share, marking its 64th straight year of increases, with the next dividend payable June 9 to holders of record on May 26.
